<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217801</url>
  </required_header>
  <id_info>
    <org_study_id>OND/CR/021/08-09/01906</org_study_id>
    <nct_id>NCT01217801</nct_id>
  </id_info>
  <brief_title>Two Way Bioequivalence Study Under Fed Conditions</brief_title>
  <official_title>Open-label Randomized, Two Way Crossover Bioequivalence Study to Compare Ondansetron Orally Dissolving FilmStrip 8mg With Zofran Orally Disintegrating Tablets 8 mg in 48 Healthy, Adult, Participants Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MonoSol Rx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aquestive Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the single dose bioequivalence of Ondansetron ODFS 8mg
      with Zofran ODT® (Containing Ondansetron 8 mg) in healthy, male and female adult, human study
      participants under fed conditions.

      The purpose is to monitor clinical status, adverse events, laboratory investigations and to
      assess relative safety and tolerance of ondansetron formulations under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label randomized, single oral dose, two way crossover bioequivalence study to compare
      ondansetron Orally Dissolving FilmStrip (ODFS) 8mg with Zofran Orally Disintegrating Tablets
      [ODT® (Containing Ondansetron 8 mg)] in 48 healthy, adult, human study participants under fed
      conditions. Volunteers who signed the consent form and showed their willingness to
      participate in the study were enrolled. Volunteers who satisfied the inclusion and exclusion
      criteria and found to be healthy on physical examination with laboratory investigation values
      within reference limits were considered eligible to be admitted into the study. Study
      participants were fasted for 10 hours prior to dosing in both periods. Dosing was conducted
      as per the randomization schedule in each period under fed conditions.A washout period of 7
      days was observed between the two periods.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Plasma Concentration</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Calculation of the AUC-Time Curve will be conducted to determine bio-equivalence.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ondansetron (ODFS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of Ondansetron Orally Dissolving Filmstrip 8 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zofran (ODT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of Zofran (Ondansetron) ODT Orally Disintegrating Tablets 8 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron (ODFS)</intervention_name>
    <description>Ondansetron Orally Dissolving Filmstrip Ondansetron (ODFS)</description>
    <arm_group_label>Ondansetron (ODFS)</arm_group_label>
    <other_name>Zuplenz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron (ODT)</intervention_name>
    <description>Ondansetron Orally Disintegrating Tablet Ondanestron (ODT)</description>
    <arm_group_label>Zofran (ODT)</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  provide written informed consent.

          -  healthy adult within 18-45 years of age (inclusive).

          -  Body mass index of ≥ 18.5 kg/m2 and ≤ 25 kg/m2, with body weight not less than 50 kg.

          -  systolic blood pressure with upper limit of less than 140 mmHg and lower limit of more
             than or equal to 90 mm Hg.

          -  normal health as determined by medical history and physical examination performed
             within 15 days prior to the dosing of period 1.

          -  Normal ECG, chest X-ray and vital signs.

          -  If study volunteer is a female and is of child bearing potential practicing an
             acceptable method of birth control for the duration of the study.

        Exclusion Criteria:

          -  The study participants were excluded based on the following criteria:

               -  incapable of understanding the informed consent.

               -  history of hypersensitivity or idiosyncratic reaction to study drug or any other
                  related drug.

               -  evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
                  function

               -  volunteers with a history of tuberculosis, epilepsy, asthma (during past 5
                  years), diabetes, psychosis or glaucoma .

               -  smokes regularly more than ten cigarettes daily

               -  taken over the counter or prescribed medications

               -  history of any psychiatric illness, which may impair the ability to provide
                  written, informed consent or full participation.

               -  history of alcohol or substance abuse within the last 5 years.

               -  clinically significant abnormal values of laboratory parameters.

               -  positive urine screen for drugs of abuse at the time of admission check-in for
                  each period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudershan Vishwanath</last_name>
    <role>Study Director</role>
    <affiliation>Vimta VHS Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vimta VHS Research Centre</name>
      <address>
        <city>Adyar</city>
        <state>Chenni</state>
        <zip>600 113</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <results_first_submitted>July 25, 2011</results_first_submitted>
  <results_first_submitted_qc>March 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 2, 2017</results_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy adult study participants between 18-45 years (inclusive) of age who were willing to participate in the study by providing written informed consent</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ondansetron Orally Dissolving Filmstrip Then ODT</title>
          <description>Ondansetron Orally Dissolving Filmstrip 8 mg then 7 days then Ondansetron Orally Disintegrating Tablet 8 mg measure AUC</description>
        </group>
        <group group_id="P2">
          <title>Ondansetron Orally Disintegrating Tablet Then OD Film</title>
          <description>Ondansetron Orally Disintegrating Tablet AUC Ondansetron 8 mg then 7 days then Ondansetron Orally Disintegrating Film 8 mg measure AUC</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is a crossover study so the total number of participants is 48</population>
      <group_list>
        <group group_id="B1">
          <title>Ondanestron Orally Dissolving Filmstrip</title>
          <description>Ondanestron Orally Dissolving Filmstrip (8 mg) followed by a 7 day wash out and then administered Ondanestron Orally Disintegrating tablets (8 mg); AUCs for each period will be calculated.</description>
        </group>
        <group group_id="B2">
          <title>Ondanestron Orally Disintegrating Tablet</title>
          <description>Ondanestron Orally Disintegrating Tablet (8 mg) followed by a 7 day wash out and then administered Ondanestron Orally Dissolving Filmstrip (8 mg); AUCs for each period will be calculated.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.78" spread="5.8"/>
                    <measurement group_id="B2" value="26.78" spread="5.8"/>
                    <measurement group_id="B3" value="26.78" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under Plasma Concentration</title>
        <description>Calculation of the AUC-Time Curve will be conducted to determine bio-equivalence.</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All that completed a period</population>
        <group_list>
          <group group_id="O1">
            <title>Film</title>
            <description>AUC film strip</description>
          </group>
          <group group_id="O2">
            <title>Tablet</title>
            <description>tablet AUC</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration</title>
          <description>Calculation of the AUC-Time Curve will be conducted to determine bio-equivalence.</description>
          <population>All that completed a period</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213.7" spread="47.8"/>
                    <measurement group_id="O2" value="225.9" spread="49.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear mixed effect model, log transformed AUC, LSMeans for treatment Film and Tablet, the difference between the LSMeans and 90%CI calculated and transformed to geometric means, ratio estimates and 90%CI</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Regression, Linear</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>93.77</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.15</ci_lower_limit>
            <ci_upper_limit>98.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>study period Plus 30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ondanestron Orally Dissolving Filmstrip</title>
          <description>Ondanestron Orally Dissolving Filmstrip AUC</description>
        </group>
        <group group_id="E2">
          <title>Ondanestron Orally Disintegrating Tablet</title>
          <description>Ondanestron Orally Disintegrating Tablet AUC</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>medra</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <description>film</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>film</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>URTI</sub_title>
                <description>post study end received both dose forms</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs</name_or_title>
      <organization>Par Pharmaceutical</organization>
      <phone>800-828-9393</phone>
      <email>DrugInfo@strativapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

